We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Glucose Monitor for Measuring Blood Sugar Levels Reconfigured for Use as SARS-CoV-2 Antibody Detector

By LabMedica International staff writers
Posted on 14 Oct 2020
A trio of scientists - a pharmacologist, a biomedical engineer, and a biophysicist - at the Johns Hopkins University (Baltimore, MD, USA) has developed a system for using everyday glucose monitors to detect COVID-19 antibodies.

The scientists are pooling their knowledge to design a device that can detect whether a person has antibodies linked to SARS-CoV-2, the virus that causes COVID-19. More...
To develop an antibody detector that can be deployed rapidly and inexpensively across the globe, the researchers were inspired by a test that is already used by millions of people: a glucose monitor. People with diabetes use glucose monitors to measure their blood sugar levels by taking a tiny prick of blood from their finger and placing it on a paper test strip that is inserted into the monitor. This same type of tool could be reconfigured to detect glucose in a series of chemical reactions that occur when antibodies are detected in the blood, according to the researchers.

First, the researchers developed a test strip that contains the "spike" protein from the surface of the SARS-CoV-2 virus. They add a drop of blood from a patient, and the spike proteins on the test strip bind with COVID-19-related antibodies present in the blood. Then, the researchers dip the strip into a tube with an enzyme that binds to the COVID-19 antibodies. After washing off the excess enzyme, the scientists insert the strip into a solution containing a molecule that is transformed by the enzyme into glucose. Finally, a commercial glucose monitor reads the amount of glucose present on the test strip, which is a surrogate for COVID-19 antibodies present in the patient's blood sample. The researchers are continuing to refine and test the patent-pending technology.

"Learning from the present and planning for the future, we are pursuing the development of a biosensing platform that will hopefully helps us better monitor infection spread for the current and future national epidemics," said Netz Arroyo, assistant professor of pharmacology and molecular sciences, who is leading the study.

Related Links:
Johns Hopkins University


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
New
Hematology Consumables
Bioblood Devices
New
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: The GenoPredict assay from Predicta Biosciences is available to Tempus Life Sciences partners to support exploratory research and clinical development programs (photo courtesy of Shutterstock)

Partnership Expands Ultrasensitive WGS Assay for for Hematologic Malignancies and MRD Monitoring

Tempus AI and Predicta Biosciences announced the commercial expansion of a co-branded whole‑genome sequencing assay GenoPredicta, which is intended for comprehensive genomic characterization of hematologic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.